Journal ArticleDOI
Targeting public neoantigens for cancer immunotherapy.
Alexander H. Pearlman,Alexander H. Pearlman,Michael S. Hwang,Maximilian F. Konig,Emily Han-Chung Hsiue,Emily Han-Chung Hsiue,Jacqueline Douglass,Jacqueline Douglass,Sarah R. DiNapoli,Sarah R. DiNapoli,Brian J. Mog,Chetan Bettegowda,Drew M. Pardoll,Sandra B. Gabelli,Nicholas Papadopoulos,Kenneth W. Kinzler,Bert Vogelstein,Shibin Zhou +17 more
- Vol. 2, Iss: 5, pp 487-497
Reads0
Chats0
TLDR
The opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them are reviewed.Abstract:
Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients’ tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mutations in cancer driver genes. The latter approaches target proteins that are indispensable for tumor growth, and each therapeutic agent can be applied to numerous patients. Here we review the opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them. Zhou and colleagues discuss the opportunities and challenges in targeting public neoantigens for cancer immunotherapy.read more
Citations
More filters
Journal ArticleDOI
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs
Mark Yarmarkovich,Quinlen F. Marshall,John M. Warrington,Rasika Premaratne,Alvin Farrel,David Groff,Wei Li,Moreno Di Marco,Erin Runbeck,Hau Truong,Jugmohit S. Toor,Sarvind Tripathi,Son Nguyen,Helena Shen,Tiffany Noel,Nicole L. Church,Amber K. Weiner,Nathan M. Kendsersky,Daniel Martinez,Rebecca Weisberg,Molly Christie,Laurence C. Eisenlohr,Kristopher R. Bosse,Kristopher R. Bosse,Dimiter S. Dimitrov,Stefan Stevanovic,Nikolaos G. Sgourakis,Ben R. Kiefel,John M. Maris,John M. Maris +29 more
TL;DR: In this article, a peptide-centric chimeric antigen receptor (CAR) was proposed to target unmutated peptide QYNPIRTTF, discovered on HLA-A*24:02, derived from the neuroblastoma dependency gene and master transcriptional regulator PHOX2B.
Journal ArticleDOI
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
TL;DR: The differing mechanisms of T cell antigen recognition and signal transduction mediated through CARs and TCRs are described and both classical and emerging pre-clinical strategies for antigen-specific TCR discovery, enhancement, and validation are discussed.
Journal ArticleDOI
Neoantigens: promising targets for cancer therapy
TL;DR: Neoantigens are newly formed antigens generated by tumor cells as a result of various tumor-specific alterations, such as genomic mutation, dysregulated RNA splicing, disordered post-translational modification, and integrated viral open reading frames as mentioned in this paper .
Journal ArticleDOI
Thermal immuno-nanomedicine in cancer
Zhe Yang,Di Gao,Jing Zhao,Gaojie Yang,Mingli Guo,Yiming Wang,Xuechun Ren,Jong Seung Kim,L. Jin,Zhongmin Tian,Jing Zhang +10 more
Journal ArticleDOI
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic
TL;DR: In this review, Bewersdorf and Abdel-Wahab discuss the development of promising new molecular targeted approaches for AML, including menin inhibition, novel IDH1/2 inhibitors, and preclinical means to target TET2, ASXL1, and RNA splicing factor mutations.
References
More filters
Journal ArticleDOI
A vaccine targeting mutant IDH1 in newly diagnosed glioma.
Michael Platten,Michael Platten,Lukas Bunse,Lukas Bunse,Antje Wick,Theresa Bunse,Theresa Bunse,Lucian Le Cornet,Inga Harting,Felix Sahm,Khwab Sanghvi,Chin Leng Tan,Isabel Poschke,Edward W. Green,Sune Justesen,Geoffrey A. Behrens,Michael O. Breckwoldt,Angelika Freitag,Lisa-Marie Rother,Anita Schmitt,Oliver Schnell,Jörg Hense,Martin Misch,Dietmar Krex,Stefan Stevanovic,Ghazaleh Tabatabai,Joachim P. Steinbach,Martin Bendszus,Andreas von Deimling,Michael Schmitt,Wolfgang Wick +30 more
TL;DR: In this paper, an IDH1(R132H)-specific peptide vaccine (IDH1-vac) was used to induce specific therapeutic T helper cell responses that are effective against the most common IDH 1 mutation in diffuse gliomas, which harbours a shared clonal neoepitope.
Journal ArticleDOI
The Human Vaccines Project: A roadmap for cancer vaccine development
Pedro Romero,Jacques Banchereau,Nina Bhardwaj,Mark I. Cockett,Mary L. Disis,Glenn Dranoff,Eli Gilboa,Scott A. Hammond,Robert M. Hershberg,Alan J. Korman,Pia Kvistborg,Cornelis J. M. Melief,Ira Mellman,A. Karolina Palucka,Irina Redchenko,Harlan Robins,Federica Sallusto,Theodore Schenkelberg,Stephen P. Schoenberger,Jeffrey A. Sosman,Özlem Türeci,Benoît Van den Eynde,Benoît Van den Eynde,Wayne C. Koff,George Coukos +24 more
TL;DR: It is argued that a concerted international effort is necessary to understand the human antitumor immune response and achieve clinically effective cancer vaccines.
Journal ArticleDOI
Evolutionary pressure against MHC class II binding cancer mutations
Rachel Marty Pyke,Wesley K. Thompson,Rany M. Salem,Joan Font-Burgada,Joan Font-Burgada,Maurizio Zanetti,Hannah Carter +6 more
TL;DR: It is demonstrated that the M HC-II genotype constrains the mutational landscape during tumorigenesis in a manner complementary to MHC-I, emphasizing the central role of MHC -II presentation in tumor evolution.
Journal ArticleDOI
Targeting a neoantigen derived from a common TP53 mutation
Emily Han-Chung Hsiue,Emily Han-Chung Hsiue,Katharine M. Wright,Katharine M. Wright,Jacqueline Douglass,Jacqueline Douglass,Michael S. Hwang,Michael S. Hwang,Brian J. Mog,Alexander H. Pearlman,Alexander H. Pearlman,Suman Paul,Sarah R. DiNapoli,Sarah R. DiNapoli,Maximilian F. Konig,Qing Wang,Qing Wang,Annika Schaefer,Annika Schaefer,Michelle S. Miller,Michelle S. Miller,Andrew D. Skora,Andrew D. Skora,P. Aitana Azurmendi,P. Aitana Azurmendi,Michael B. Murphy,Liu Qiang,Liu Qiang,Evangeline Watson,Evangeline Watson,Yana Li,Drew M. Pardoll,Chetan Bettegowda,Nickolas Papadopoulos,Kenneth W. Kinzler,Bert Vogelstein,Sandra B. Gabelli,Shibin Zhou +37 more
TL;DR: In this paper, the authors describe the identification of an antibody highly specific to the most common TP53 mutation (R175H, in which arginine at position 175 is replaced with histidine) in complex with a common human leukocyte antigen-A (HLA-A) allele on the cell surface.
Journal ArticleDOI
Developing neoantigen-targeted T cell-based treatments for solid tumors.
TL;DR: The prospect of targeting somatic tumor mutations to promote T cell destruction of cancer must contend with the biology that not all tumor-expressed ‘neoepitopes’ actually generate neoantigens that can be functionally recognized and provoke an effective immune response.